Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1186104 | 0.98 | MEN1 (0.61) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL27519099 | 0.93 | NPC1 (0.67) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL9717016 | 0.93 | MEN1 (0.56) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL7328271 | 0.91 | ACR (0.58) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL7330789 | 0.89 | ACR (0.59) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL20764440 | 0.85 | MEN1 (0.67) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL27671251 | 0.83 | PRSS1 (0.62) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL6339534 | 0.83 | SMN1; SMN2 (0.64) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL10956570 | 0.82 | KMT2A (0.56) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL7563606 | 0.82 | F2 (0.45) | MEN1KMT2AMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0287036-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | claimed |
| EP-0287036-A2 | New pharmaceutical compositions comprising esters or amides as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-10-19 | — | — | EP | claimed |
| WO-2023148783-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-08-10 | — | — | WO | disclosed |
| US-10023544-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10017487-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9975903-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9969705-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-9969709-B2 | Guanidinobenzoic acid ester compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20180072694-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20160355494-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-08 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-5110602-A | Solution or suspension in middle chain glyceride to inhibit degradation by digestive enzymes | ONO PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0287036-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-5004612-A | Dissolved in a middle chain glyceride of a fatty acid | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4889723-A | SUSPENDED OR DISSOLVED IN GLYCERIDE; STABILITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0287036-A2 | New pharmaceutical compositions comprising esters or amides as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072694-A1 | FUSED HETEROCYCLIC COMPOUND | VIP, DPP4, TMPRSS15 | MEN1 1222/4885KMT2A 1239/4885MAPT 4491/4885 |
| US-20160355494-A1 | FUSED HETEROCYCLIC COMPOUND | VIP, DPP4, TMPRSS15 | MEN1 1441/4885KMT2A 2730/4885MAPT 4632/4885 |
| US-10017487-B2 | Fused heterocyclic compound | VIP, DPP4, TMPRSS15 | MEN1 1222/4885KMT2A 1239/4885MAPT 4491/4885 |
| US-20170349605-A1 | CONDENSED HETEROCYCLIC COMPOUND | VIP, TMPRSS15, MMP2 | MEN1 862/4885KMT2A 1181/4885MAPT 4104/4885 |
| US-10023544-B2 | Heterocyclic compound | MMP2, DPP4, TMPRSS15 | MEN1 1193/4885KMT2A 2541/4885MAPT 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.